What Is Non-DOT Drug Testing?
Non-DOT drug testing refers to any workplace drug and alcohol testing program that operates outside the federal rules set by the U.S. Department of Transportation. Where DOT testing applies to safety-sensitive employees in regulated industries — commercial truck drivers, pipeline workers, airline crew, and others covered by 49 CFR Part 40 — non-DOT testing covers everyone else: office staff, warehouse workers, construction crews, healthcare employees, and virtually any role an employer chooses to include in a testing program.
Because federal DOT rules do not apply, employers running non-DOT programs have significant flexibility in how they design and operate testing. That flexibility is an advantage, but it also means employers are fully responsible for the decisions they make — including which drugs to test for, what cutoff levels to use, when testing occurs, and how results are handled.
Non-DOT vs. DOT Testing: Key Differences
Understanding the differences helps employers make better decisions about their own programs, especially if they manage a mixed workforce that includes both DOT-regulated and non-regulated employees.
| Factor | DOT Testing | Non-DOT Testing |
|---|---|---|
| Governing authority | 49 CFR Part 40 and agency rules | Employer policy, state and local law |
| Test panel | 5-panel (federally mandated substances) | Employer’s choice — 5, 10, 12-panel or custom |
| Cutoff levels | Federal cutoffs set by SAMHSA/HHS Mandatory Guidelines | Employer sets cutoffs, often SAMHSA-equivalent |
| Collection method | Urine only (oral fluid added in 2023) | Urine, oral fluid, or hair — employer’s choice |
| MRO required | Yes, federally required | Not federally required, but strongly recommended |
| Random testing | Mandatory for covered employees | Optional, but common and legally defensible |
| Documentation | Strict chain-of-custody and recordkeeping rules | No federal standard, but same rigor is best practice |
One important note: non-DOT results cannot be used to satisfy DOT testing requirements. If you operate a mixed program, the two tracks must remain entirely separate.
Why Employers Run Non-DOT Testing Programs
Employers choose to implement non-DOT drug testing for several reasons, none of which require a federal mandate to be valid:
- Workplace safety. Impaired employees are more likely to be involved in accidents, injure coworkers, and damage equipment. Testing reduces that risk, particularly in physically demanding or equipment-intensive environments.
- Insurance and liability. Many workers’ compensation carriers offer premium discounts to employers with documented drug-free workplace programs. Some states have drug-free workplace statutes that provide additional protections against workers’ comp claims following a positive test.
- Quality and productivity. Substance use is associated with absenteeism, reduced output, and higher turnover. A consistent testing program supports a more reliable workforce.
- Customer and contract requirements. Government contractors, construction subcontractors, and employers in highly regulated sectors often face drug-free workplace requirements from clients even when federal DOT rules do not apply.
- Legal defensibility. A well-documented non-DOT program — with a written policy, consistent application, and MRO oversight — gives employers a strong foundation if a testing decision is ever challenged.
Choosing a Test Panel
The test panel determines which drugs are screened. Non-DOT employers are not limited to the federal 5-panel; they can select the panel that matches their risk environment and policy goals.
5-Panel
Screens for marijuana (THC), cocaine, amphetamines/methamphetamine, opiates (codeine, morphine, heroin), and phencyclidine (PCP). This is the same set of substances tested under DOT rules and remains the most common starting point for non-DOT programs.
10-Panel
Adds benzodiazepines (Valium, Xanax), barbiturates, methadone, propoxyphene, and methaqualone to the standard 5-panel. A 10-panel is common in healthcare, safety-sensitive manufacturing, and employers with a history of prescription drug misuse in their workforce.
12-Panel
Extends the 10-panel with oxycodone/oxymorphone and buprenorphine. Oxycodone is not detected by standard opiate screening at typical cutoffs, so employers concerned about prescription opioid misuse should consider adding it explicitly.
Extended Opiates and Custom Panels
Fentanyl, tramadol, and other synthetic opioids are not included in standard panels. Employers in industries with high overdose risk — construction, logistics, hospitality — may work with a TPA to add specific analytes. Custom panels require a laboratory that offers those specific assays and an MRO experienced in reviewing those substances.
Oral Fluid Panels
Oral fluid testing detects recent use rather than historical exposure. Typical detection windows are 24–48 hours for most substances, compared to 2–7 days or longer for urine. Oral fluid is particularly useful for post-accident and reasonable suspicion testing, where recent impairment is the concern rather than off-duty use. Note: the DOT added oral fluid collection as an authorized method under 49 CFR Part 40 effective January 2023; non-DOT programs may follow the same procedures or adapt them to their own policy.
Standard Cutoff Levels
Cutoffs determine when a result is reported as positive. Non-DOT employers typically adopt SAMHSA/HHS federal cutoff levels as a baseline, since they are well-established, legally defensible, and familiar to MROs. All DOT drug tests must also be analyzed by an HHS-certified laboratory; non-DOT employers are strongly advised to use the same certified labs. Employers can set lower cutoffs for certain substances, but doing so increases the likelihood of positive results for individuals using prescription medications at therapeutic doses — which raises MRO complexity and potential legal exposure.
Common initial test cutoffs (urine, ng/mL): marijuana metabolite 50, cocaine metabolite 150, amphetamines 500, opiates 2000, PCP 25, oxycodone 100, benzodiazepines 200. Confirmatory cutoffs are lower. Work with your MRO to set cutoffs appropriate for your program before testing begins.
Testing Occasions
Non-DOT employers can test at any point a reasonable policy justifies. Common occasions include:
Pre-Employment
The most common testing occasion. Most employers require a negative result before a conditional offer becomes final. Oregon employers may test applicants for marijuana and deny employment based on a positive result, even though recreational marijuana is legal in the state.
Reasonable Suspicion
Triggered when a trained supervisor observes specific, articulable signs of impairment — slurred speech, impaired coordination, the odor of alcohol, or erratic behavior. The observation must be documented in writing before the test is ordered. Reasonable suspicion testing is one of the most important tools in a non-DOT program and one of the most commonly mishandled. Supervisors must be trained to recognize the signs and to document them correctly.
Post-Accident
Conducted after a workplace incident that results in injury, property damage, or near-miss. The policy should define what triggers testing — a recordable injury, a certain threshold of property damage, or any incident requiring medical attention beyond first aid. Testing should occur as soon as possible after the incident while maintaining the safety of all involved.
Random
Employees are selected through a truly random mechanism (typically a third-party random selection service) and notified on the same day they are selected. The unpredictability is what makes random testing an effective deterrent. Pools should be clearly defined in the policy, and the selection process must be documented.
Return-to-Duty and Follow-Up
When an employee who tested positive or violated policy is permitted to return to work, a return-to-duty test is typically required before reinstatement. Follow-up testing — unannounced and at a frequency defined in a return-to-duty agreement — continues afterward. Unlike DOT programs, non-DOT employers set the terms of these tests themselves, but they should be documented in writing and applied consistently.
Oregon-Specific Considerations
Oregon employers operating non-DOT programs face a specific legal landscape that differs from the federal baseline and from many other states.
- Marijuana and pre-employment testing. Oregon employers may still require pre-employment drug tests that include marijuana and may decline to hire based on a positive marijuana result. However, some Oregon localities and certain industries have added restrictions. Employers should confirm their obligations under Oregon Revised Statutes and any applicable local ordinances before implementing or changing marijuana testing policies.
- Medical marijuana. Oregon law does not currently require employers to accommodate medical marijuana use in the workplace. Employers may enforce zero-tolerance marijuana policies for safety-sensitive positions.
- Workers’ compensation. Oregon has a drug-free workplace program under ORS Chapter 656 that, when properly implemented, allows employers to deny or reduce workers’ compensation benefits following a work-related injury if a positive drug test contributed to the incident.
- Privacy. Oregon’s employment laws require careful handling of test results. Results must be kept confidential, stored separately from personnel files, and disclosed only to those with a legitimate need to know.
Laws change. Employers should review their non-DOT policy with legal counsel familiar with Oregon employment law at least annually, and whenever a significant change occurs — a new substance legalization, a court ruling, or a change in company operations.
The Role of an MRO in Non-DOT Testing
A Medical Review Officer is a licensed physician trained to review laboratory drug test results. While federal law requires MRO review for DOT tests, there is no federal mandate for non-DOT programs. Using one anyway is strongly advisable.
An MRO protects employers by interviewing donors who report a legitimate prescription before a result is reported as positive. Without MRO review, an employer who receives a positive result directly from the lab and acts on it — terminating or disciplining the employee — may face liability if the employee was taking a lawfully prescribed medication. An MRO also verifies the integrity of the collection and can identify specimens that were diluted, substituted, or adulterated.
For non-DOT programs, the MRO applies the same medical judgment as in DOT testing. The main difference is that the specific regulatory thresholds and interview requirements of 49 CFR Part 40 do not technically apply, so the employer and MRO should agree in advance on how to handle edge cases.
Common Mistakes in Non-DOT Programs
No written policy. Verbal testing policies are unenforceable and expose employers to discrimination claims. Every non-DOT program must start with a written policy acknowledged by employees.
Inconsistent application. Testing some employees but not others for the same position or occasion — without a documented, job-related reason — creates disparate treatment claims. The policy must define who is in scope and when, and it must be applied the same way every time.
Skipping MRO review. Receiving lab results directly and acting on them without MRO review is one of the most common and costly mistakes in non-DOT programs. A positive result that an MRO would have canceled due to a valid prescription becomes a wrongful termination case.
Poorly trained supervisors. Reasonable suspicion testing is only as good as the supervisors who initiate it. Undertrained supervisors either miss impairment they should catch or order tests without sufficient documentation — either outcome creates problems. Supervisor training should be documented and repeated periodically.
Outdated policy. A policy written before Oregon’s marijuana laws changed, before an acquisition added new job classifications, or before a new safety-sensitive role was created may no longer match what the employer is actually doing. Review and update the policy annually.
How A WorkSAFE Service Supports Non-DOT Programs
A WorkSAFE Service works with Oregon employers to design, implement, and manage non-DOT drug testing programs from the ground up. Our services include:
- Written policy development tailored to your workforce and risk environment
- Panel and cutoff selection guidance
- Pre-employment, random, post-accident, and reasonable suspicion testing coordination
- MRO-reviewed results with fast turnaround
- Mobile onsite collections throughout Oregon
- Access to 5,000+ certified collection sites nationwide
- Supervisor reasonable suspicion training
- Ongoing compliance review and program updates
Whether you are building a program from scratch or improving an existing one, we can help you create a testing program that is legally sound, consistently applied, and right for your workplace.
Call: 503-391-9363
Email: drugtesting@aworksafeservice.com
Contact us to discuss your non-DOT testing needs.
